Raymond James Financial Services Advisors Inc. Sells 1,973 Shares of CareDx, Inc (NASDAQ:CDNA)

Raymond James Financial Services Advisors Inc. decreased its position in CareDx, Inc (NASDAQ:CDNA) by 3.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,817 shares of the company’s stock after selling 1,973 shares during the period. Raymond James Financial Services Advisors Inc. owned approximately 0.09% of CareDx worth $610,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Raymond James & Associates boosted its stake in CareDx by 10.5% in the 4th quarter. Raymond James & Associates now owns 76,837 shares of the company’s stock worth $922,000 after purchasing an additional 7,270 shares in the last quarter. SG Americas Securities LLC bought a new position in CareDx during the 4th quarter valued at about $259,000. Public Employees Retirement System of Ohio lifted its stake in CareDx by 67.5% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 98,848 shares of the company’s stock valued at $692,000 after acquiring an additional 39,843 shares during the period. Vanguard Group Inc. lifted its stake in CareDx by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,138,591 shares of the company’s stock valued at $28,970,000 after acquiring an additional 50,667 shares during the period. Finally, Citigroup Inc. lifted its stake in CareDx by 7.1% during the 3rd quarter. Citigroup Inc. now owns 132,560 shares of the company’s stock valued at $928,000 after acquiring an additional 8,768 shares during the period.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “overweight” rating and set a $15.00 target price on shares of CareDx in a research note on Wednesday. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $13.50.

CareDx Trading Up 5.5 %

CareDx stock opened at $8.28 on Thursday. The firm has a 50 day moving average of $9.69 and a 200 day moving average of $9.16. The firm has a market capitalization of $428.74 million, a price-to-earnings ratio of -2.34 and a beta of 1.42. CareDx, Inc has a 12-month low of $4.80 and a 12-month high of $12.93.

CareDx (NASDAQ:CDNA) last released its earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($1.97). The firm had revenue of $65.57 million during the quarter, compared to analysts’ expectations of $63.66 million. CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The company’s revenue was down 20.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.34) earnings per share. On average, analysts predict that CareDx, Inc will post -1.59 EPS for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.